SCHEMBL1702476

SCHEMBL1702476

N#Cc1ccc(Nc2ccc3cccc(Cl)c3n2)nc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 2/20 0.44
TYK2 P29597 2/20 0.43
XPO1 O14980 2/20 0.41
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
ALOX12 P18054 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
KLF5 Q13887 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
FLT3 P36888 1/20 0.39
IRAK4 Q9NWZ3 1/20 0.39
JAK2 O60674 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1702294 0.79 XPO1 (0.50) XPO1KMT2AKDM4ENPC1LMNA
SCHEMBL1705808 0.79 BTK (0.44) CHEK1TYK2XPO1KMT2AKDM4E
SCHEMBL29568127 0.79 XPO1 (0.50) XPO1KMT2AKDM4ENPC1LMNA
SCHEMBL1701948 0.77 KDM4E (0.57) CHEK1TYK2KMT2AKDM4ENPC1
Hydrochloric Acid SCHEMBL13518597 0.76 KDM4E (0.56) CHEK1TYK2KMT2AKDM4ENPC1
SCHEMBL1702103 0.76 XPO1 (0.47) CHEK1XPO1KMT2AKDM4ENPC1
SCHEMBL31219517 0.76 RPS6KA3 (0.46) XPO1KMT2AKDM4ENPC1LMNA
SCHEMBL1705885 0.76 RPS6KA3 (0.46) XPO1KMT2AKDM4ENPC1LMNA
SCHEMBL22266118 0.76 FLT3 (0.54) TYK2KMT2AKDM4ELMNATSHR
SCHEMBL30033495 0.76 KMT2A (0.68) TYK2XPO1KMT2AKDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440546-B1 COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA ABIVAX (FR) 2022-12-28 EP claimed
EP-2440547-B1 New chemical molecules that inhibit the splicing mechanism for the treatment of diseases resulting from splicing defects ABIVAX (FR) 2022-11-30 EP claimed
EP-2440545-B1 COMPOUNDS USEFUL FOR TREATING CANCER ABIVAX (FR) 2019-04-24 EP claimed
US-9908869-B2 Compounds useful for treating aids ABIVAX (FR) 2018-03-06 US claimed
US-9827237-B2 Compounds useful for treating diseases caused by retroviruses ABIVAX (FR) 2017-11-28 US claimed
US-20160151348-A1 COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES ABIVAX (FR) 2016-06-02 US claimed
EP-3016656-A1 BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES ABIVAX (FR) 2016-05-11 EP claimed
US-9108919-B2 Compounds useful for treating cancer ABIVAX (FR) 2015-08-18 US claimed
WO-2015001518-A1 BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES SPLICOS (FR) 2015-01-08 WO claimed
US-20140288120-A1 COMPOUNDS USEFUL FOR TREATING AIDS SOCIETE SPLICOS (FR) 2014-09-25 US claimed
US-20140080831-A1 COMPOUNDS USEFUL FOR TREATING CANCER CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (FR) 2014-03-20 US claimed
US-20120329796-A1 COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA SOCIETE SPLICOS (FR) 2012-12-27 US claimed
US-20120283265-A1 COMPOUNDS USEFUL FOR TREATING AIDS SOCIETE SPLICOS (FR) 2012-11-08 US claimed
US-20120277230-A1 COMPOUNDS USEFUL FOR TREATING CANCER SOCIETE SPLICOS (FR) 2012-11-01 US claimed
EP-2440546-A2 COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA Société Splicos (FR) 2012-04-18 EP claimed
EP-2440547-A2 COMPOUNDS USEFUL FOR TREATING AIDS Société Splicos (FR) 2012-04-18 EP claimed
EP-2440545-A2 COMPOUNDS USEFUL FOR TREATING CANCER Société Splicos (FR) 2012-04-18 EP claimed
WO-2010143169-A2 COMPOUNDS USEFUL FOR TREATING AIDS SOCIÉTÉ SPLICOS (FR) 2010-12-16 WO claimed
WO-2010143168-A2 COMPOUNDS USEFUL FOR TREATING CANCER SOCIÉTÉ SPLICOS (FR) 2010-12-16 WO claimed
WO-2010143170-A2 COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA SOCIÉTÉ SPLICOS (FR) 2010-12-16 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283265-A1 COMPOUNDS USEFUL FOR TREATING AIDS CBR1, CNR1, CBR3 CHEK1 4611/4885TYK2 3606/4885XPO1 824/4885
US-20140288120-A1 COMPOUNDS USEFUL FOR TREATING AIDS NR1H3, NR3C1, NR3C2 CHEK1 4681/4885TYK2 4405/4885XPO1 1048/4885
US-20120277230-A1 COMPOUNDS USEFUL FOR TREATING CANCER CBR1, CBR3, NCOR1 CHEK1 2759/4885TYK2 4018/4885XPO1 448/4885
US-20120329796-A1 COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA NR2C2, NCOR2, NR4A2 CHEK1 3195/4885TYK2 4104/4885XPO1 1488/4885
US-20160151348-A1 COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES RCOR1, CBR1, RCOR3 CHEK1 4306/4885TYK2 2656/4885XPO1 761/4885
US-20140080831-A1 COMPOUNDS USEFUL FOR TREATING CANCER NR1H4, NR1H3, NCOR1 CHEK1 3439/4885TYK2 4684/4885XPO1 958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.